Trial · NCT01990677
Eplerenone for the Treatment of Central Serous Chorioretinopathy
NCT01990677, Not applicable, Completed, Wills Eye; results first posted 2017-06-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Eplerenone for the Treatment of Central Serous Chorioretinopathy. Trials, record NCT01990677. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01990677
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Eplerenone for the Treatment of Central Serous Chorioretinopathy
- NCT number
- NCT01990677
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 108 participants, actual
- Lead sponsor
- Wills Eye
- Conditions
- Central Serous Chorioretinopathy
- Interventions
- 25mg Eplerenone, Placebo
- First posted
- 2013-11-21
- Last updated
- 2018-11-07
- Results first posted
- 2017-06-29
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change in Maximal Subretinal Fluid Height Based on Spectral Domain Optical Coherence Tomography (OCT) Measurement. | Baseline and 2 months | Mean change in maximal subretinal fluid height based on spectral domain OCT from baseline to month 2 in chronic central serous chorioretinopathy (CSCR) patients receiving placebo versus eplerenone. |
| Secondary | Mean Change in Subfoveal Fluid Height Based on OCT Measurement | Baseline and Month 2 | Mean change in subfoveal fluid height based on spectral domain OCT measurement from baseline to month 2 in chronic CSCR patients receiving placebo versus eplerenone. |
| Other | Proportion of Eyes Demonstrating a Reduction in Subretinal Fluid on OCT | Baseline and Month 2 | Proportion of eyes having a decrease in subretinal fluid on spectral domain OCT from baseline to month 2 in chronic CSCR patients receiving placebo versus eplerenone. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Change in Maximal Subretinal Fluid Height Based on Spectral Domain Optical Coherence Tomography (OCT) Measurement. | Baseline and 2 months | Significant acute data collection missing therefore only chronic arm data analysis was reviewed and entered into results data. | microns | MEAN |
| SECONDARY | Mean Change in Subfoveal Fluid Height Based on OCT Measurement | Baseline and Month 2 | Significant acute data collection missing therefore only chronic arm data analysis was reviewed and entered into results data. | microns | MEAN |
| OTHER_PRE_SPECIFIED | Proportion of Eyes Demonstrating a Reduction in Subretinal Fluid on OCT | Baseline and Month 2 | Significant acute data collection missing therefore only chronic arm data analysis was reviewed and entered into results data. | Eyes | COUNT_OF_UNITS |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change in Maximal Subretinal Fluid Height Based on Spectral Domain Optical Coherence Tomography (OCT) Measurement. | 25mg Eplerenone- Chronic CSCR Diagnosis | Baseline | 139.3 | Standard Deviation 58.7 | microns |
| Mean Change in Maximal Subretinal Fluid Height Based on Spectral Domain Optical Coherence Tomography (OCT) Measurement. | Placebo- Chronic CSCR Diagnosis | Baseline | 135.9 | Standard Deviation 21.8 | microns |
| Mean Change in Maximal Subretinal Fluid Height Based on Spectral Domain Optical Coherence Tomography (OCT) Measurement. | 25mg Eplerenone- Chronic CSCR Diagnosis | Month 2 | 51.8 | Standard Deviation 52.2 | microns |
| Mean Change in Maximal Subretinal Fluid Height Based on Spectral Domain Optical Coherence Tomography (OCT) Measurement. | Placebo- Chronic CSCR Diagnosis | Month 2 | 172.3 | Standard Deviation 88.8 | microns |
| Mean Change in Subfoveal Fluid Height Based on OCT Measurement | 25mg Eplerenone- Chronic CSCR Diagnosis | Baseline | 121.4 | Standard Deviation 75.0 | microns |
| Mean Change in Subfoveal Fluid Height Based on OCT Measurement | Placebo- Chronic CSCR Diagnosis | Baseline | 92.1 | Standard Deviation 47.4 | microns |
| Mean Change in Subfoveal Fluid Height Based on OCT Measurement | 25mg Eplerenone- Chronic CSCR Diagnosis | Month 2 | 29.4 | Standard Deviation 34.0 | microns |
| Mean Change in Subfoveal Fluid Height Based on OCT Measurement | Placebo- Chronic CSCR Diagnosis | Month 2 | 134.0 | Standard Deviation 105.9 | microns |
| Proportion of Eyes Demonstrating a Reduction in Subretinal Fluid on OCT | 25mg Eplerenone- Chronic CSCR Diagnosis | 11 | Eyes | ||
| Proportion of Eyes Demonstrating a Reduction in Subretinal Fluid on OCT | Placebo- Chronic CSCR Diagnosis | 1 | Eyes |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 25mg Eplerenone- Chronic CSCR Diagnosis | 12 | |
| Overall Study | STARTED | Placebo- Chronic CSCR Diagnosis | 6 | |
| Overall Study | COMPLETED | 25mg Eplerenone- Chronic CSCR Diagnosis | 10 | |
| Overall Study | COMPLETED | Placebo- Chronic CSCR Diagnosis | 5 | |
| Overall Study | NOT COMPLETED | 25mg Eplerenone- Chronic CSCR Diagnosis | 2 | |
| Overall Study | NOT COMPLETED | Placebo- Chronic CSCR Diagnosis | 1 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dizziness | General disorders | 25mg Eplerenone- Chronic CSCR Diagnosis | 1 | 12 | 1 |
| other | Dizziness | General disorders | Placebo- Chronic CSCR Diagnosis | 0 | 6 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 25mg Eplerenone- Chronic CSCR Diagnosis | 0 | 12 |
| Total, all-cause mortality | Placebo- Chronic CSCR Diagnosis | 0 | 6 |
| Total, other adverse events | 25mg Eplerenone- Chronic CSCR Diagnosis | 1 | 12 |
| Total, other adverse events | Placebo- Chronic CSCR Diagnosis | 0 | 6 |
| Total, serious adverse events | 25mg Eplerenone- Chronic CSCR Diagnosis | 0 | 12 |
| Total, serious adverse events | Placebo- Chronic CSCR Diagnosis | 0 | 6 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40522203 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| 25mg Eplerenone- Chronic CSCR Diagnosis vs Placebo- Chronic CSCR Diagnosis: deaths from any cause | Trial comparisons |
| 25mg Eplerenone- Chronic CSCR Diagnosis vs Placebo- Chronic CSCR Diagnosis: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01990677
GET https://conductscience.org/api/trials/v1/NCT01990677/registered